We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
XEMBIFY (Grifols Australia Pty Ltd)
Product name
XEMBIFY
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
143 (255 working days)
Active ingredients
human immunoglobulin G
Registration type
NCE/NBE
Indication
Indications for subcutaneous administration (SCIg)
XEMBIFY (solution for subcutaneous injection) is indicated as replacement therapy in adult and paediatric patients for: